top of page
Search
Hereditary Pancreatic Cancer Risk Management: Interpreting Surveillance Findings in High-Risk Patients
Mehul Trivedi, MD - Communications Committee Member We were delighted to welcome Dr. Fay Kastrinos, Professor of Medicine at Columbia University and Director of the GI Cancer Risk and Prevention Clinic and Pancreatic Cancer Prevention and Genetics Program, who shared her expertise on current strategies, outcomes, and emerging approaches to pancreatic cancer screening in high-risk individuals. We began by reviewing the goals of pancreatic cancer screening, emphasizing the impo
CGA-IGC
4 days ago3 min read
Connecting to Latin American Genetic Counseling and Hereditary Cancer Resources This Hispanic Heritage Month!
Chandrika Kurpad, MS, LGCG - Communications Committee Member Hispanic Heritage Month provides an opportunity to recognize and celebrate the diverse communities, cultures, and contributions of Latin America. It is also an opportunity to highlight resources that support healthcare professionals working to expand knowledge, education, and access to genetic counseling and hereditary cancer care across the region. For those interested in genetic counseling, cancer genetics, and he
CGA-IGC
5 days ago4 min read
Adding a COX-2 Inhibitor to Neoadjuvant Immunotherapy in dMMR/MSI-H Colorectal Cancer: What PICC-2 Tells Us
Alessandro Mannucci, MD, CGA-IGC Communications Committee Member Source: Hu H, Shen X, Li Y, et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2026;27:1020–30. Why this trial matters Over the last five years, neoadjuvant PD-1 blockade has completely changed the management o
CGA-IGC
Oct 76 min read
Hereditary Cancer Awareness Week 2026: What We’re Learning About Cascade Testing!
Megan Dwyer, MS, CGC, CGA-IGC Communications Committee member National Hereditary Cancer Week takes place from September 27 to October 3, with a focus on raising awareness of inherited cancer risk and promoting early detection through genetic testing and screening. A central part of this effort is cascade testing: testing family members after a cancer-related gene mutation is identified in a relative. Done well, it catches at-risk individuals before cancer develops, enabling
CGA-IGC
Sep 283 min read
Hereditary Cancer Awareness Week 2026: Strengthening Knowledge, Supporting Patients with CGA-IGC
Hereditary Cancer Awareness Week begins September 27! CGA-IGC will mark the week with educational content, patient perspectives and practical resources for healthcare providers for their practice. From NCCN Guidelines updates and cascade testing to patient stories, infographics, specialist care resources and research collaborations, we’ll highlight opportunities to strengthen knowledge, support conversations and connect our community with care and research. A heartfelt thank
CGA-IGC
Sep 274 min read
2026 Hereditary Cancer Awareness Week: What's New in NCCN Version 1.2026? Key Updates in Hereditary GI Cancer
Jennifer Fijor, ARNP, CGA-IGC Communications Committee member The NCCN Guidelines for Genetic/Familial High-Risk Assessment were updated in June 2026, with real changes across colorectal, endometrial, gastric, and now esophageal cancer for the first time. Here's what changed, and where the field still doesn't agree: 1. Universal Lynch syndrome assessment expands, but it wasn't an easy vote Version 1.2026 now recommends universal Lynch syndrome assessment for all patients with
CGA-IGC
Sep 274 min read
bottom of page